What are the recommended dosing regimens, dose adjustments for renal impairment, monitoring schedule, management of adverse effects, drug interaction precautions, and contraceptive counseling for Olaparib in patients with BRCA‑mutated ovarian, breast, or prostate cancer?

Olaparib Dosing and Management

For patients with BRCA-mutated ovarian, breast, or prostate cancer, olaparib should be dosed at 300 mg orally twice daily (tablet formulation), with dose reduction to 200 mg twice daily in patients with moderate renal impairment (CrCl 31-50 mL/min). 1

Standard Dosing Regimen

• Standard dose: 300 mg orally twice daily (tablet formulation)
• This represents a reduction from the original 400 mg twice daily capsule formulation, as the tablet formulation achieves equivalent or superior steady-state exposure with better tolerability 2
• The 300 mg twice daily tablet dose was selected as the recommended Phase III dose because 65% of patients on 400 mg tablets eventually required dose reduction to 300 mg due to hematological toxicity 2

Dose Adjustments for Renal Impairment

Mild renal impairment (CrCl 51-80 mL/min):

• No dose adjustment required
• The 24% increase in AUC is not clinically significant 1

Moderate renal impairment (CrCl 31-50 mL/min):

• Reduce dose to 200 mg twice daily
• Exposure increases by 44% in this population, necessitating dose reduction 1
• Monitor these patients carefully for adverse effects

Severe renal impairment (CrCl <30 mL/min):

• Insufficient data; use with extreme caution or avoid

Monitoring Schedule

Hematologic monitoring (most critical):

• Complete blood count at baseline
• Monthly CBC for the first year of treatment
• Anemia is the most common grade ≥3 adverse event (17% of patients) 3
• Thrombocytopenia and neutropenia also occur frequently 3, 4

Clinical monitoring:

• Assess for fatigue, nausea, vomiting, and decreased appetite at each visit (these are the most common adverse events, occurring in 42-70% of patients) 3, 4
• Monitor for rare but serious events including myelodysplastic syndrome/acute myeloid leukemia

Management of Adverse Effects

Common adverse events (occurring in >20% of patients):

• Fatigue (50-70%)
• Nausea (42-66%)
• Vomiting (26-39%)
• Decreased appetite (26-36%)
• Anemia (37%)
• Neutropenia (26%)
• Thrombocytopenia (21%)

Dose modification strategy:

• For grade ≥3 adverse events or intolerable grade 2 events: interrupt treatment
• Once resolved to grade ≤1, consider restarting at reduced dose
• Dose reduction sequence: 300 mg → 250 mg → 200 mg → 150 mg twice daily
• Dose re-escalation is feasible: After adverse events resolve, 5 of 8 patients who required dose reduction successfully tolerated re-escalation 5
• In very elderly or frail patients, consider starting at 150 mg twice daily, as demonstrated effective in a 92-year-old patient who achieved 40-month durable response 6

Anemia management:

• Most common grade ≥3 toxicity
• Supportive care with transfusions as needed
• Dose interruption/reduction if grade ≥3
• Consider erythropoiesis-stimulating agents in select cases

Drug Interaction Precautions

Avoid strong/moderate CYP3A inhibitors:

• Olaparib is metabolized by CYP3A4/5
• If strong CYP3A inhibitor is unavoidable, reduce olaparib dose to 100 mg twice daily
• If moderate CYP3A inhibitor is unavoidable, reduce to 150 mg twice daily

Avoid strong/moderate CYP3A inducers:

• May significantly reduce olaparib exposure
• Use alternative agents without CYP3A induction

Contraceptive Counseling

Women of childbearing potential:

• Must use effective contraception during treatment and for 6 months after the last dose
• Olaparib can cause fetal harm based on mechanism of action and animal studies

Male patients with female partners of childbearing potential:

• Should use effective contraception during treatment and for 3 months after the last dose

Treatment Setting-Specific Considerations

Breast cancer (adjuvant setting):

• Olaparib can be given concurrently with endocrine therapy 7
• Indicated for germline BRCA1/2-mutated, high-risk early breast cancer after completion of neoadjuvant or adjuvant chemotherapy 7

Ovarian cancer (maintenance therapy):

• PARP inhibitor use limited to those with BRCA1/2 mutations if not previously used (Category 1) 8
• For second-line maintenance, olaparib is now restricted to patients with germline or somatic BRCA mutations following FDA request 8
• Patients who most benefit are those receiving PARP inhibitors in the frontline setting 8

Response rates by tumor type (in BRCA-mutated cancers):

• Ovarian cancer: 31% response rate 3
• Breast cancer: 13% response rate 3
• Pancreatic cancer: 22% response rate 3
• Prostate cancer: 50% response rate 3

Common Pitfalls to Avoid

• Do not use the capsule formulation dosing (400 mg twice daily = 16 capsules/day) when tablets are available; the tablet formulation at 300 mg twice daily provides equivalent exposure with better tolerability
• Do not overlook renal function: Always calculate creatinine clearance before initiating therapy and adjust dose accordingly
• Do not continue full dose in face of grade ≥3 hematologic toxicity: Dose reduction is often necessary and does not appear to compromise efficacy
• Do not assume all PARP inhibitors are interchangeable: Olaparib has specific dosing and indication differences from niraparib and rucaparib